Savara enters into non-dilutive debt financing for up to $200m with hercules capital

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with hercules capital, inc. (nyse: htgc), for up to $200 million. access to the additional capital strengthens savara's balance sheet following the submission of the biologics license application (bla) to the u.s. food and drug administration (fda) for molbreevi* as a tre.
SVRA Ratings Summary
SVRA Quant Ranking